NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/20/2024
Back to search
Official data from USPTO
MEDILINK
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
08/20/2024
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
01/21/2022
Registration date
08/20/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/20/2024
Last transaction
08/20/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/09/2022
First use in commerce
06/09/2022
Drawing code
5
Owner type
99
Owner location
Suzhou, Jiangsu, CN
Examiner
KRUSSMAN, IAN
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "MEDILINK".
Holders and representatives
Holders
MediLink Therapeutics(Suzhou)Co.,Ltd.
Representatives
Timothy T. Wang NI, WANG & MASSAND, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposesfor treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparationselixirs for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Tumor suppressing agents
Publications
History of USPTO decisions and trademark events.
25 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/20/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/15/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/15/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/02/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/02/2024
ALIE
ASSIGNED TO LIE
07/02/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
11/06/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
11/06/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/08/2023
GNRT
NON-FINAL ACTION E-MAILED
08/08/2023
CNRT
SU - NON-FINAL ACTION - WRITTEN
08/08/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/03/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/03/2023
IUAF
USE AMENDMENT FILED
07/18/2023
EISU
TEAS STATEMENT OF USE RECEIVED
07/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/31/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/06/2022
PUBO
PUBLISHED FOR OPPOSITION
12/06/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/16/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/01/2022
DOCK
ASSIGNED TO EXAMINER
10/28/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/26/2022
NWAP
NEW APPLICATION ENTERED
01/25/2022
Continuous trademark protection
Get notified about every new filing that threatens MEDILINK or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.